Oral antihypertensive trial design and analysis under the pediatric exclusivity provision

American Heart Journal

Volumn 144, Issue 4, 2002, Pages 608-614

  Pasquali, Sara K ^a   Sanders, Stephen P ^a   Li, Jennifer S ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMILORIDE; AMLODIPINE; ANTIHYPERTENSIVE AGENT; BENAZEPRIL; BENDROFLUMETHIAZIDE; BETAXOLOL; BISOPROLOL; CANDESARTAN; CAPTOPRIL; CARTEOLOL; CARVEDILOL; CHLOROTHIAZIDE; CHLORTALIDONE; CLONIDINE; DIAZOXIDE; DILTIAZEM; DOXAZOSIN; ENALAPRIL; ENALAPRILAT; EPROSARTAN; ETACRYNIC ACID; FELODIPINE; FENOLDOPAM; FOSINOPRIL; GUANABENZ; GUANFACINE; HYDRALAZINE; HYDROCHLOROTHIAZIDE; HYDROFLUMETHIAZIDE; UNINDEXED DRUG;

ARTICLE; CHILD; CLINICAL TRIAL; DOSE RESPONSE; DRUG INFORMATION; DRUG LEGISLATION; HUMAN; HYPERTENSION; PATIENT SELECTION; PEDIATRICS; PRACTICE GUIDELINE; PRIORITY JOURNAL; PUBLICATION;

EID: 0036790165     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-8703(02)00130-8     Document Type: Article

References (15)

1. Lee PY, Alexander KP, Hammill BG, et al. Representation of elderly persons and women in published randomized trials of acute coronary syndromes. JAMA 2001;286:708-13.
2. US Food and Drug Administration, Department of Health and Human Services. The Pediatric Exclusivity Provision, January 2001 Status Report to Congress. Available at: http://www.fda.gov/ cder/pediatric/. Accessed August 7, 2002.
3. Sanders SP. Conducting pediotric cardiovascular trials. Am Heart J 2001;142:218-23.
4. United States Congress. Best Pharmaceuticals for Children Act. January 4, 2002. Available at: http://www.fda.gov/cder/pediatric. Accessed August 7, 2002.
5. US Food and Drug Administration, Center for Drug Evaluation and Research. Update of list of approved drugs for which additional pediatric information may produce health benefits in the pediatric population. May 20, 2001. Available at: http://www.fda.gov/ cder/pediatric/peddrugsfinal.htm. Accessed August 7, 2002.
6. Kay JD, Sinaiko AR, Daniels SR. Pediatric hypertension. Am Heart J 2001;142:422-32.
7. Flynn JT. Pediatric use of antihypertensive medications: much more to learn. Cur Ther Res 2001;62:314-28.
8. US Food and Drug Administration, Center for Drug Evaluation and Research. Sample written request for oral antihypertensives. Available at: http://www.fda.gov/cder/pediatric/htnwr.htm.
9. Ross LF, Newburger JW, Sanders SP. Ethical issues in pediatric trials. Am Heart J 2001;142:233-6.
10. American Academy of Pediatrics. Guidelines for the ethical conduct of studies to evaluate drugs in pediatric populations. Pediatrics 1995;95:286-94.
11. Vitiello B, Jensen PS. Medication development and testing in children and adolescents: current problems, future directions. Arch Gen Psychiatry 1997;54:871-6.
12. Al-Khatib SM, Califf RM, Hasselblad V, et al. Placebo-controls in short-term clinical trials of hypertension. Science 2001;292:2013-5.
13. Sorof JM, Cargo P, Graepel J, et al. Beta-blocker/thiazide combination for treatment of hypertensive children: a randomized, double-blind, placebo-controlled trial. Pediatr Nephrol 2002;17:345-50.
14. Public Citizen. Patently offensive: Congress set to extend monopoly patents for Cipro and other drugs. November 9, 2001. Available at: http://www.citizen.org/congress/reform/drug_patents/pediatric/ articles.cfm?lD=6435. Accessed August 7, 2002.
15. Ward R. America Academy of Pediatrics testimony before the United States Senate committee on health, education, labor, and pensions. May 8, 2001. Available at: http://www.aap.org/ advocacy/washing/testimonymay8thBWard.html. Accessed August 7, 2002.